These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6799944)

  • 21. Psychotropic activity of N-methyl-2-amino-4-phosphonobutyric acid (N-methyl AP4).
    Zalewska A; Winnicka MM; Wiśniewski K
    Pol J Pharmacol; 1996; 48(4):415-23. PubMed ID: 9112682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal dopamine application increases dopaminergic activity in the neostriatum and nucleus accumbens and enhances motor activity in the open field.
    de Souza Silva MA; Topic B; Huston JP; Mattern C
    Synapse; 2008 Mar; 62(3):176-84. PubMed ID: 18081176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of ibopamine on central nervous system in mice and rats.
    Ferrini R; Miragoli G; Sala R; Reggiani A
    Arzneimittelforschung; 1986 Feb; 36(2A):327-30. PubMed ID: 3707643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of nootropic agents on the lowering of the spasm threshold after a single ethanol application].
    Dienel A; Andreas K; Schmidt J
    Biomed Biochim Acta; 1984; 43(10):1179-84. PubMed ID: 6441574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of nootropic drugs on the age-dependent potassium-coupling of transmitter release.
    Wustmann C; Blaschke M; Rudolph E; Fischer HD; Schmidt J
    Biomed Biochim Acta; 1990; 49(7):619-24. PubMed ID: 2149265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two distinctive apomorphine-induced phenotypes in the Roman high- and low-avoidance rats.
    Giménez-Llort L; Cañete T; Guitart-Masip M; Fernández-Teruel A; Tobeña A
    Physiol Behav; 2005 Nov; 86(4):458-66. PubMed ID: 16154604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor.
    Izzo E; Sanna PP; Koob GF
    Pharmacol Biochem Behav; 2005 Aug; 81(4):701-8. PubMed ID: 16005056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of nootropic drugs on brain cholinergic and dopaminergic transmission.
    Pavlík A; Benesová O; Dlohozková N
    Act Nerv Super (Praha); 1987 Mar; 29(1):62-5. PubMed ID: 3035858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cholinergic effects of nootropics].
    Funk KF; Schmidt J
    Biomed Biochim Acta; 1988; 47(4-5):417-21. PubMed ID: 3149192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity?
    Surmann A; Havemann-Reinecke U
    J Neural Transm Suppl; 1995; 45():143-55. PubMed ID: 8748620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On some mechanisms of antihypoxic actions of nootropic drugs.
    Fischer HD; Schmidt J; Wustmann C
    Biomed Biochim Acta; 1984; 43(4):541-3. PubMed ID: 6435609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behavioral and neurochemical components of nicotine sensitization following 15-day pretreatment: studies on contextual conditioning.
    Reid MS; Ho LB; Berger SP
    Behav Pharmacol; 1998 Mar; 9(2):137-48. PubMed ID: 10065933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Central activity of 2-amino-3-phosphonopropionic acid (AP3) and its N-methyl analog.
    Winnicka MM; Wiśniewski K; Kupczyk-Subotkowska L; Subotkowski W; Mastalerz P
    Pol J Pharmacol; 1994; 46(5):395-401. PubMed ID: 7894525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine D3 receptor antisense oligodeoxynucleotide potentiates imipramine-induced dopaminergic behavioural supersensitivity.
    D'Aquila PS; Panin F; Castelli MP; Serra G
    Behav Pharmacol; 2006 Mar; 17(2):101-6. PubMed ID: 16495718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Central action of adrenaline.
    Jagiełło-Wójtowicz E
    Acta Physiol Pol; 1981; 32(2):169-80. PubMed ID: 7196677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Memory impairment induced by combined disturbance of noradrenergic and dopaminergic neurotransmissions: effects of nootropic drugs.
    Lazarova-Bakarova MB; Petkova BP; Todorov IK; Petkov VD
    Acta Physiol Pharmacol Bulg; 1991; 17(1):29-34. PubMed ID: 1667717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Behavioral changes induced by repeated administration of mazindol, an anorexiant, in rats].
    Kawakami Y; Suemaru K; Kawasaki H; Gomita Y
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Aug; 16(4):139-43. PubMed ID: 8905803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of methylglucamine orotate on intracranial self-stimulation.
    Wetzel W; Matthies H
    Acta Biol Med Ger; 1982; 41(5):465-9. PubMed ID: 6814132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucocorticoids modulate behavioral effects induced by dopaminergic agonists in rats.
    Danilczuk Z; Ossowska G; Wróbel A; Lupina T
    Pol J Pharmacol; 2001; 53(5):467-73. PubMed ID: 11990064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of chronic treatment with psychotropic drugs on behavioral changes by social isolation.
    Oehler J; Jähkel M; Schmidt J
    Pol J Pharmacol Pharm; 1985; 37(6):841-9. PubMed ID: 3938535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.